|
Dr. Sluzky joined BioMarin in February 2003 and currently serves as vice president of Quality and Analytical Chemistry. Her responsibilities include oversight of Quality Control, Quality Assurance, Validation and Analytical Chemistry groups. Prior to coming to BioMarin, Dr. Sluzky was Director of Analytical and Formulation Development at Onyx Pharmaceuticals, where she was responsible for developing in-process, characterization and stability assays for recombinant adenoviruses, as well as managing formulation development efforts. From 1992 to 1999, Dr. Sluzky was involved in pharmaceutical research and development for various biotechnology products ranging from small molecules and peptides to proteins, first at Scios and then at COR Therapeutics (now Millennium Pharmaceuticals). Dr. Sluzky has contributed to numerous regulatory submissions and peer reviewed publications. She holds a Ph.D. in Chemical Engineering from MIT and a B.S. (also in Chemical Engineering) from Stanford University. | 